Mecasermin (Ipsen)

美卡舍明 (益普生)

Report date: 2025/01/08 10:37:37

Base Information

Drug NameMecasermin (Ipsen)
Drug Alias NameMecasermina (Ipsen)Mecaserminum (Ipsen)Somatomedin-1 (Ipsen)IncrelexFK-780 +[8] 
ClassificationBiologics > Protein drugs > Recombinant protein > Recombinant hormone
Mechanisms of ActionInsulin-like growth factor I receptor agonists
TargetsInsulin-like growth factor I receptor
Therapy Area/IndicationsPhelan-McDermid syndromeAutism Spectrum DisorderFailure to Thrive +[6] 
Global Approved IndicationsFailure to ThriveLaron Syndrome
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date2005/08/30
Country/TerritoryUnited StatesFranceEU
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesGenentech Inc
China Registration ClassN/A

Develop Information

Active CompaniesEton Pharmaceuticals IncIpsen PharmaIpsen Inc
Inactive CompaniesIpsenIcahn School Of Medicine At Mount SinaiNational Institute Of Allergy And Infectious Diseases (Niaid)
Active IndicationsFailure to ThriveLaron Syndrome
Inactive IndicationsPhelan-McDermid syndromeAutism Spectrum DisorderGrowth Disorders +[4] 

Other Information

ATC CodeH01AC03
Related LinksWikipediaDrugBankKEGG